Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupirocin nasal rinses for surgically recalcitrant Staphylococcus aureus-positive chronic rhinosinusitis
ACTRN12611000994987Phase 3Recruiting
- Sponsor
- The Queen Elizabeth Hospital
- Start
- Jan 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of mupirocin in chronic rhinosinusitis (CRS) and Staphylococcus aureus infection (2 arms), sponsored by The Queen Elizabeth Hospital. Primary endpoint: Primary: Staphylococcus aureus infection status. Started Jan 2010; status: recruiting.
02
Drugs
mupirocin
03
Conditions
chronic rhinosinusitis (CRS)Staphylococcus aureus infection
Beyond the preview
Go deeper on ACTRN12611000994987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000994987.